Identification and overcoming rituximab resistance in diffuse large B-cell lymphoma using next-generation sequencing
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge. Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasing concentrations of rituximab in a rituximab-sensitive cell line (RSCL). When the same dose of rituximab was administered, RRCL showed a smaller decrease in cell viability and apoptosis than RSCL. To determine the differences in gene expression between RSCL and RRCL, we performed next-generation sequencing. Results: In total, 1,879 differentially expressed genes were identified, and in the over-representation analysis of Consensus- PathDB, mitogen-activated protein kinase (MAPK) signaling pathway showed statistical significance. MAPK13, which encodes the p38δ protein, was expressed more than four-fold in RRCL. Western blot analysis revealed that phosphop38 expression mainwas increased in RRCL, and when p38 inhibitor was administered, phosphop38 expression was significantly decreased. Therefore, we hypothesized that p38 MAPK activation was associated with rituximab resistance. Previous studies have suggested that p38 is associated with NF-κB activation. Deferasirox has been reported to inhibit NF-κB activity and suppress phosphorylation of the MAPK pathway. Furthermore, it also has cytotoxic effects on various cancers and synergistic effects in overcoming drug resistance. In this study, we confirmed that deferasirox induced dose-dependent cytotoxicity in both RSCL and RRCL, and the combination of deferasirox and rituximab showed a synergistic effect in RRCL at all combination concentrations. Conclusions: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.
Abstract
Background/Aims: Although rituximab, an antiCD20 monoclonal antibody, has dramatically improved the clinical outcomes of diffuse large B-cell lymphoma, rituximab resistance remains a challenge. Methods: We developed a rituximab-resistant cell line (RRCL) by sequential exposure to gradually increasing concentrations of rituximab in a rituximab-sensitive cell line (RSCL). When the same dose of rituximab was administered, RRCL showed a smaller decrease in cell viability and apoptosis than RSCL. To determine the differences in gene expression between RSCL and RRCL, we performed next-generation sequencing. Results: In total, 1,879 differentially expressed genes were identified, and in the over-representation analysis of Consensus- PathDB, mitogen-activated protein kinase (MAPK) signaling pathway showed statistical significance. MAPK13, which encodes the p38δ protein, was expressed more than four-fold in RRCL. Western blot analysis revealed that phosphop38 expression mainwas increased in RRCL, and when p38 inhibitor was administered, phosphop38 expression was significantly decreased. Therefore, we hypothesized that p38 MAPK activation was associated with rituximab resistance. Previous studies have suggested that p38 is associated with NF-κB activation. Deferasirox has been reported to inhibit NF-κB activity and suppress phosphorylation of the MAPK pathway. Furthermore, it also has cytotoxic effects on various cancers and synergistic effects in overcoming drug resistance. In this study, we confirmed that deferasirox induced dose-dependent cytotoxicity in both RSCL and RRCL, and the combination of deferasirox and rituximab showed a synergistic effect in RRCL at all combination concentrations. Conclusions: We suggest that p38 MAPK, especially p38δ, activation is associated with rituximab resistance, and deferasirox may be a candidate to overcome rituximab resistance.
참고문헌 (29)
- 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study", Journal of Pathology and Translational Medicine, 45(3), pp.254~260 (2011), 대한병리학회
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Colosia A, "Clinical efficacy and safety in relapsed", refractory diffuse large B-cell lymphoma : a systematic literature review, 2014, pp.14, 343~355
- Sarkozy C, "Management of relapsed", refractory DLBCL, 2018, pp.31, 209~216
- Jun Ho Yi, "Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas", Blood Research, 56, pp.1~4 (2021), 대한혈액학회[DOI]
- Rezvani AR, "Rituximab resistance", Best Pract Res Clin Haematol, 24, pp.203~216 (2011)
- Pérez-Callejo D, "Action and resistance of monoclonal CD20antibodies therapy in B-cell Non-Hodgkin Lymphomas", Cancer Treat Rev, 41, pp.680~689 (2015)
- Tsai PC, "Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma", Clin Cancer Res, 18, pp.1039~1050 (2012)
- Czuczman MS, "Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels", Clin Cancer Res, 14, pp.1561~1570 (2008)
- van Meerten T, "Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity", Clin Cancer Res, 12, pp.4027~4035 (2006)
- Takei K, "Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines", Leuk Res, 30, pp.625~631 (2006)
- Bedford MR, "Iron chelation in the treatment of cancer : a new role for deferasirox?", J Clin Pharmacol, 53, pp.885~891 (2013)
- 최종권, "Effects of oral iron chelator deferasirox on human malignant lymphoma cells", Blood Research, 47(3), pp.194~201 (2012), 대한혈액학회
- Bonavida B, "Rituximab-induced inhibition of antiapoptotic cell survival pathways : implications in chemo", immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions, 2007, pp.26, 3629~3636
- Jazirehi AR, "Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy", Cancer Res, 67, pp.1270~1281 (2007)
- Vega MI, "Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription : pivotal role of p38 MAPK in drug resistance", Oncogene, 23, pp.3530~3540 (2004)
- Pedersen IM, "The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism", Blood, 99, pp.1314~1319 (2002)
- Ding H, "P38 mitogen activated protein kinase expression and regulation by interleukin-4 in human B cell non-Hodgkin lymphomas", J Hematop, 2, pp.195~204 (2009)
- Vega GG, "P38 MAPK expression and activation predicts failure of response to CHOP in patients with diffuse large B-Cell lymphoma", BMC Cancer, 15, pp.722~ (2015)
- Vega GG, "Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein : direct cytotoxicity and synergy with chemotherapy", Int J Oncol, 47, pp.1735~1748 (2015)
- Vega GG, "p38 MAPK and NF-κB survival pathways as targets for action of rituximab in vivo in a xenographic model", Blood, 130(Supplement 1), pp.5199~ (2017)
- Turturro F, "Constitutive NF-κB Activation underlines major mechanism of drug resistance in relapsed refractory diffuse large B cell lymphoma", Biomed Res Int, 2015, pp.484537~ (2015)
- Knittel G, "Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma", Eur J Haematol, 97, pp.499~510 (2016)
- Kennedy R, "Aberrant activation of NF-κB signalling in aggressive lymphoid malignancies", Cells, 7, pp.189~ (2018)
- Messa E, "Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging", Haematologica, 95, pp.1308~1316 (2010)
- Al-Rousan RM, "Deferasirox removes cardiac iron and attenuates oxidative stress in the iron-overloaded gerbil", Am J Hematol, 84, pp.565~570 (2009)
- Ohyashiki JH, "The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1", Cancer Sci, 100, pp.970~977 (2009)
- Dae Sik Kim, "Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells", The Korean Journal of Internal Medicine, 31(2), pp.357~366 (2016), 대한내과학회[DOI]
- Yoo Jin Na, "Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells", The Korean Journal of Internal Medicine, 36, pp.196~206 (2021), 대한내과학회[DOI]